|
09/25/2023
|
Summary ToggleEledon Pharmaceuticals Announces Use of Tegoprubart anti-CD40L Antibody in Second-ever Transplant of Genetically Modified Heart from a Pig to a Human
|
|
09/20/2023
|
Summary ToggleEledon Pharmaceuticals to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conference
|
|
09/11/2023
|
Summary ToggleEledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors
|
|
09/06/2023
|
Summary ToggleEledon Pharmaceuticals Announces Publication of Data Showing Treatment with Tegoprubart Promotes Kidney and Islet Allograft Survival and Function in Nonhuman Primates
|
|
09/05/2023
|
Summary ToggleEledon Pharmaceuticals Announces First Participant Dosed in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Rejection in Kidney Transplantation
|
|
08/16/2023
|
Summary ToggleEledon Pharmaceuticals Announces Dosing of 10th Patient in Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation
|
|
08/10/2023
|
Summary ToggleEledon Pharmaceuticals Reports Second Quarter 2023 Operating and Financial Results
|
|
06/02/2023
|
Summary ToggleEledon Pharmaceuticals to Present at Jefferies Healthcare Conference
|
|
05/11/2023
|
Summary ToggleEledon Pharmaceuticals Reports First Quarter 2023 Operating and Financial Results
|
|
05/04/2023
|
Summary ToggleEledon Pharmaceuticals to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023
|
